Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Paddison, Patrick J  [Clear All Filters]
2023
Kuppers DA, Linton J, Espinosa SOrtiz, McKenna KM, Rongvaux A, Paddison PJ. Gene knock-outs in human CD34+ hematopoietic stem and progenitor cells and in the human immune system of mice. PLoS One. 2023;18(6):e0287052.
Mitchell K, Sprowls SA, Arora S, Shakya S, Silver DJ, Goins CM, Wallace L, Roversi G, Schafer R, Kay K, et al. WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma. Genes Dev. 2023.
2020
Hoellerbauer P, Kufeld M, Arora S, Wu H-J, Feldman HM, Paddison PJ. A simple and highly efficient method for multi-allelic CRISPR-Cas9 editing in primary cell cultures. Cancer Rep (Hoboken). 2020:ecnr21269.
2015
Nayak RC, Trump LR, Aronow BJ, Myers K, Mehta P, Kalfa T, Wellendorf AM, C Valencia A, Paddison PJ, Horwitz MS, et al. Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. J Clin Invest. 2015.
2013
Betschinger J, Nichols J, Dietmann S, Corrin PD, Paddison PJ, Smith A. Exit from Pluripotency Is Gated by Intracellular Redistribution of the bHLH Transcription Factor Tfe3. Cell. 2013;153(2):335-47.
Danovi D, Folarin A, Gogolok S, Ender C, Elbatsh AMO, Engström PG, Stricker SH, Gagrica S, Georgian A, Yu D, et al. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. PLoS One. 2013;8(10):e77053.